stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
Conexeu Sciences Inc. (CNXU) P/E ratio
Conexeu Sciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNXU Conexeu Sciences Inc. | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)